Literature DB >> 15335291

Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective.

Ziding Feng1, Ross Prentice, Sudir Srivastava.   

Abstract

The development and validation of clinically useful biomarkers from high-dimensional genomic and proteomic information pose great research challenges. Present bottlenecks include: that few of the biomarkers showing promise in initial discovery were found to warrant subsequent validation; and biomarker validation is expensive and time consuming. Biomarker evaluation should proceed in an orderly fashion to enhance rigor and efficiency. A molecular profiling approach, although promising, has a high chance of yielding biased results and overfitted models. Specimens from cohorts or intervention trials are essential to eliminate biases. The high cost for biomarker validation motivates some novel study design features, including sequential filtering and DNA pooling. For data analysis, logistic regression (in particular, boosting logistic regression) has features of robustness against model misspecification, and has resistance to model overfitting. Model assessment and cross-validation are critical components of data analysis. Having an independent test set is a vital feature of study design.

Mesh:

Substances:

Year:  2004        PMID: 15335291     DOI: 10.1517/14622416.5.6.709

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  35 in total

1.  Biomarkers for Early Cancer Detection - Methodological Aspects.

Authors:  Paolo Verderio; Anita Mangia; Chiara M Ciniselli; Paola Tagliabue; Angelo Paradiso
Journal:  Breast Care (Basel)       Date:  2010-04-21       Impact factor: 2.860

2.  Higher levels of GATA3 predict better survival in women with breast cancer.

Authors:  Nam K Yoon; Erin L Maresh; Dejun Shen; Yahya Elshimali; Sophia Apple; Steve Horvath; Vei Mah; Shikha Bose; David Chia; Helena R Chang; Lee Goodglick
Journal:  Hum Pathol       Date:  2010-12       Impact factor: 3.466

3.  Improving the quality of biomarker discovery research: the right samples and enough of them.

Authors:  Margaret S Pepe; Christopher I Li; Ziding Feng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-02       Impact factor: 4.254

Review 4.  Molecular screening of cancer: the future is here.

Authors:  Sudhir Srivastava
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Multistage sampling for latent variable models.

Authors:  Duncan C Thomas
Journal:  Lifetime Data Anal       Date:  2007-10-18       Impact factor: 1.588

6.  Scientific frontiers: emerging technologies for salivary diagnostics.

Authors:  B J Baum; J R Yates; S Srivastava; D T W Wong; J E Melvin
Journal:  Adv Dent Res       Date:  2011-10

7.  A general framework for formal tests of interaction after exhaustive search methods with applications to MDR and MDR-PDT.

Authors:  Todd L Edwards; Stephen D Turner; Eric S Torstenson; Scott M Dudek; Eden R Martin; Marylyn D Ritchie
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

8.  Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values.

Authors:  Matthew F Buas; Christopher I Li; Garnet L Anderson; Margaret S Pepe
Journal:  Cancer Epidemiol       Date:  2018-08-10       Impact factor: 2.984

9.  Finding biomarker signatures in pooled sample designs: a simulation framework for methodological comparisons.

Authors:  Anna Telaar; Gerd Nürnberg; Dirk Repsilber
Journal:  Adv Bioinformatics       Date:  2010-07-04

Review 10.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.